A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

Inclusion Criteria: * Subjects have given written informed consent * Body mass index (BMI): ≥ 25 kg/m² * Hepatic steatosis (CAP ≥ 300) * Insulin-resistant but not diabetic subjects * Fasting plasma glucose \<126 mg/dL * Glomerular filtration rate (eGFR) ≥ 60 mL/\[min\*1.73 m²\] * Alanine amino transferase (ALT) \> 20 IU/L in females and \> 30 IU/L in males * Effective contraception Exclusion Criteria: * Evidence of another form of liver disease * Evidence of liver cirrhosis * Evidence of hepatic impairment * Positive serologic evidence of current infectious liver disease * History of excessive alcohol intake * Acute cardiovascular disease with 24 weeks prior to screening * Uncontrolled high blood pressure * Any disease which in the Investigator's opinion which in the Investigator's opinion would exclude the patient from the study * Use of non-permitted concomitant medication * Pregnancy or lactation